Hélène D’Anjou holds a Bachelor’s degree in biochemistry from UQTR and a Ph. D. in molecular biology from Université de Montréal. She worked for 8 years at Topigen Pharmaceuticals as a research scientist in biotechnology, where she contributed to the development of innovative medications to treat inflammatory and respiratory diseases. Before joining the Aligo team in November 2016, she completed a graduate microprogram in Technological Transfer Basics at Université de Sherbrooke and completed a mandate as a valorization consultant at Transfert-Tech Sherbrooke (formerly Socpra). As a technological analyst, Dr. D’Anjou now specializes in technocommercial analysis of life sciences innovations and their promotion to industrial partners. Her analyses include biomedical devices as well as technologies from the pharmaceutical, nutraceutical and biotechnology sectors.